Cargando…

The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study

BACKGROUND: Pregabalin is commonly used to relieve neuropathic pain. However, data are lacking on its efficacy for the treatment of chronic cancer pain. The purpose of this study was to determine the analgesic efficacy of pregabalin combined with morphine in the management of pancreatic cancer pain....

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Junzhu, Teng, Lei, Zhao, Liuyuan, Zou, Huichao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940217/
https://www.ncbi.nlm.nih.gov/pubmed/33594813
http://dx.doi.org/10.1002/cam4.3779
_version_ 1783661905277091840
author Dai, Junzhu
Teng, Lei
Zhao, Liuyuan
Zou, Huichao
author_facet Dai, Junzhu
Teng, Lei
Zhao, Liuyuan
Zou, Huichao
author_sort Dai, Junzhu
collection PubMed
description BACKGROUND: Pregabalin is commonly used to relieve neuropathic pain. However, data are lacking on its efficacy for the treatment of chronic cancer pain. The purpose of this study was to determine the analgesic efficacy of pregabalin combined with morphine in the management of pancreatic cancer pain. METHODS: This study reviewed patients who were prescribed morphine and 150 mg/d pregabalin between 1 January 2017 and 10 November 2018 in our institute. The primary outcomes of this study were the average pain score and dose of morphine. Secondary outcomes included characters of breakthrough cancer pain, functional interference related to pain, anxiety/depression status, and incidence of treatment‐related adverse events during the study. RESULTS: A total of 240 patients with pain related to pancreatic cancer were included in the study. The results showed that patients of both combination therapy group (pregabalin+morphine) and monotherapy group (morphine) achieved similar analgesic efficacy, demonstrated by NRS (2.4 ± 0.9 vs. 2.6 ± 0.9; combination vs. monotherapy) at the end of the study. Mean daily dose of morphine used in the combination group was significant lower compared to monotherapy group (39.5 ± 16.0 mg vs. 61.5 ± 19.3 mg, net difference 23.5, 95% CI: 18.4–28.6, p <  0.001). The change of functional interference score related to pain was significantly different between combination and monotherapy group (12.0 ± 0.4 vs. 9.8 ± 4.9; net difference, 2.3; 95% CI: 1.1–3.3; p < 0.001). Patients in combination therapy group had experienced shorter duration of breakthrough cancer pain than those in monotherapy group (X(2) p < 0.001, Cramer's V:0.36). The incidence of somnolence, dizziness, and cognitive dysfunction were significantly higher in the combination group compared to monotherapy group. No serious treatment‐related side effects were observed. CONCLUSIONS: The findings of this study supported the use of pregabalin with morphine to relieve pain in patients of pancreatic cancer.
format Online
Article
Text
id pubmed-7940217
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79402172021-03-16 The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study Dai, Junzhu Teng, Lei Zhao, Liuyuan Zou, Huichao Cancer Med Clinical Cancer Research BACKGROUND: Pregabalin is commonly used to relieve neuropathic pain. However, data are lacking on its efficacy for the treatment of chronic cancer pain. The purpose of this study was to determine the analgesic efficacy of pregabalin combined with morphine in the management of pancreatic cancer pain. METHODS: This study reviewed patients who were prescribed morphine and 150 mg/d pregabalin between 1 January 2017 and 10 November 2018 in our institute. The primary outcomes of this study were the average pain score and dose of morphine. Secondary outcomes included characters of breakthrough cancer pain, functional interference related to pain, anxiety/depression status, and incidence of treatment‐related adverse events during the study. RESULTS: A total of 240 patients with pain related to pancreatic cancer were included in the study. The results showed that patients of both combination therapy group (pregabalin+morphine) and monotherapy group (morphine) achieved similar analgesic efficacy, demonstrated by NRS (2.4 ± 0.9 vs. 2.6 ± 0.9; combination vs. monotherapy) at the end of the study. Mean daily dose of morphine used in the combination group was significant lower compared to monotherapy group (39.5 ± 16.0 mg vs. 61.5 ± 19.3 mg, net difference 23.5, 95% CI: 18.4–28.6, p <  0.001). The change of functional interference score related to pain was significantly different between combination and monotherapy group (12.0 ± 0.4 vs. 9.8 ± 4.9; net difference, 2.3; 95% CI: 1.1–3.3; p < 0.001). Patients in combination therapy group had experienced shorter duration of breakthrough cancer pain than those in monotherapy group (X(2) p < 0.001, Cramer's V:0.36). The incidence of somnolence, dizziness, and cognitive dysfunction were significantly higher in the combination group compared to monotherapy group. No serious treatment‐related side effects were observed. CONCLUSIONS: The findings of this study supported the use of pregabalin with morphine to relieve pain in patients of pancreatic cancer. John Wiley and Sons Inc. 2021-02-16 /pmc/articles/PMC7940217/ /pubmed/33594813 http://dx.doi.org/10.1002/cam4.3779 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Dai, Junzhu
Teng, Lei
Zhao, Liuyuan
Zou, Huichao
The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study
title The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study
title_full The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study
title_fullStr The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study
title_full_unstemmed The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study
title_short The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study
title_sort combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940217/
https://www.ncbi.nlm.nih.gov/pubmed/33594813
http://dx.doi.org/10.1002/cam4.3779
work_keys_str_mv AT daijunzhu thecombinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy
AT tenglei thecombinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy
AT zhaoliuyuan thecombinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy
AT zouhuichao thecombinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy
AT daijunzhu combinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy
AT tenglei combinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy
AT zhaoliuyuan combinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy
AT zouhuichao combinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy